# Eledon (ELDN) — News

ELDN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/eldn/news

## Recent headlines

- [Eledon presents updated long-term phase 2 bestow extension study results at the International Congress of the Transplantation Society](https://www.ainvest.com/news/eledon-presents-updated-long-term-phase-2-bestow-extension-study-results-international-congress-transplantation-society-2609) — AInvest Wire, Sep 22, 2026
- [Eledon Pharmaceuticals Q2 net income USD -31.63 million](https://www.ainvest.com/news/eledon-pharmaceuticals-q2-net-income-usd-31-63-million-2608) — AInvest Wire, Aug 13, 2026
- [Eledon Pharmaceuticals Q2 operating expenses USD 22.869 million](https://www.ainvest.com/news/eledon-pharmaceuticals-q2-operating-expenses-usd-22-869-million-2608) — AInvest Wire, Aug 13, 2026
- [Newcelx: FDA feedback supports planned development strategy](https://www.ainvest.com/news/newcelx-fda-feedback-supports-planned-development-strategy-2607) — AInvest Wire, Jul 1, 2026
  NewCelX Ltd. (Nasdaq: NCEL) has taken a significant step in its clinical development strategy for NCEL-101, an advanced cell therapy candidate for Type 1 Diabetes, by engaging in a Pre-IND meeting with the U.S. Food and Drug Administration (FDA). The company is working in collaboration with Eledon…
- [Natera, Eledon Pharmaceuticals reach strategic pact](https://www.ainvest.com/news/natera-eledon-pharmaceuticals-reach-strategic-pact-2606) — AInvest Wire, Jun 25, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).